An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 11 Apr 2016 Planned primary completion date changed from 1 May 2019 to 1 Apr 2019.
- 11 Apr 2016 Status changed from not yet recruiting to recruiting.
- 10 Mar 2016 Planned primary completion date changed from 1 Mar 2019 to 1 May 2019 as reported by ClinicalTrials.gov.